Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariel Hammerman

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 28, 2024
Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort studyWiessam Abu Ahmad, Ronen Arbel, Yael Wolff Sagy, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 22, 2022
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome AnalysisGal Tsaban, Hilmi Alnsasra, Aref El Nasasra, et al.
The New England Journal of Medicine|August 24, 2022
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron SurgeRonen Arbel, Yael Wolff Sagy, Moshe Hoshen, et al.
Frontiers in Pharmacology|September 18, 2025
EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemiaMagdalena Monica, Sabina Becirovic, Ioana Bianchi-Manaila, et al.
Nature Medicine|January 31, 2023
Real-world effectiveness of a single dose of mpox vaccine in malesYael Wolff Sagy, Roy Zucker, Ariel Hammerman, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2017
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataElizabeth Dudnik, Mor Moskovitz, Sameh Daher, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 27, 2023
Risk assessment of human mpox infections: retrospective cohort studyRoy Zucker, Gil Lavie, Yael Wolff-Sagy, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 28, 2024
Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort studyWiessam Abu Ahmad, Ronen Arbel, Yael Wolff Sagy, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 22, 2022
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome AnalysisGal Tsaban, Hilmi Alnsasra, Aref El Nasasra, et al.
The New England Journal of Medicine|August 24, 2022
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron SurgeRonen Arbel, Yael Wolff Sagy, Moshe Hoshen, et al.
Frontiers in Pharmacology|September 18, 2025
EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemiaMagdalena Monica, Sabina Becirovic, Ioana Bianchi-Manaila, et al.
Nature Medicine|January 31, 2023
Real-world effectiveness of a single dose of mpox vaccine in malesYael Wolff Sagy, Roy Zucker, Ariel Hammerman, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2017
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataElizabeth Dudnik, Mor Moskovitz, Sameh Daher, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 27, 2023
Risk assessment of human mpox infections: retrospective cohort studyRoy Zucker, Gil Lavie, Yael Wolff-Sagy, et al.
Pageof 6